FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE
Portfolio Pulse from Vandana Singh
The FDA has lifted the clinical hold on Pharvaris NV's IND application for deucrictibant (PHA-121) for the on-demand treatment of hereditary angioedema (HAE). This allows Pharvaris to resume RAPIDe-2 and prepare for RAPIDe-3, their global Phase 3 study. The company's stock price has increased by 14.70%.
June 26, 2023 | 4:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pharvaris' stock price increased by 14.70% after the FDA lifted the clinical hold on deucrictibant for HAE treatment.
The FDA lifting the clinical hold on Pharvaris' deucrictibant for HAE treatment is a positive development for the company, allowing them to resume RAPIDe-2 and prepare for RAPIDe-3. This news has led to an increase in the company's stock price by 14.70%, indicating a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100